Abbott Hepatitis C Combo Impressive in Small Study
> Reuters (04.02.12)::Bill Berkrot
> A combination of oral hepatitis C drugs being developed by
> Abbott Laboratories realized cure rates exceeding 90 percent in
> treatment-na?ve patients, according to a small, mid-stage study. The
> results, released Wednesday, will be presented later this month in
> Barcelona at a meeting of the European Association for the Study of the
> For 12 weeks, patients in the Phase II trial, known as
> ?Co-Pilot,? received Abbott?s protease inhibitor ABT-450, boosted by the
> antiviral drug ritonavir with its polymerase inhibitor ABT-333, and
> ribavirin, which is used in all current hepatitis C regimens. Patients?
> blood virus levels were checked 24 weeks later for a sustained virologic
> response. Those achieving SVR were considered cured.
> Eighteen of the 19 patients (95 percent) given 250 milligram
> doses of ABT-450 in their combination achieved SVR. Thirteen of 14 patients
> (93 percent) given 150 mg doses of ABT-450 achieved SVR.
> ?This demonstrates unprecedented cure rates for the most common
> form of hepatitis C infection,? said Scott Brun, Abbott?s divisional vice
> president for infectious disease development. Although confirming the
> effectiveness and safety of the drugs requires much larger trials, Abbot
> maintains it is on track to embark on Phase III testing early next year.
> In a third portion of the study concentrating on patients
> unresponsive to the standard regimen of interferon and ribavirin, 8 of 17
> (47 percent) achieved SVR. Abbott is hopeful an NS5A inhibitor it is
> testing in several all-oral combinations will boost SVR rates of previous
> Dan Bigg, Director email@example.com
> Chicago Recovery Alliance www.anypositivechange.org
> 3110 W Taylor St voice 1-312-953-3797
> Chicago IL 60612 fax 1-773-489-7448